NCT00887198 · BASELINE
Baseline characteristics
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- denoms
- counts
- group Id
- BG000
- value
- 546
- group Id
- BG001
- value
- 542
- group Id
- BG002
- value
- 1088
- units
- Participants
- groups
- description
- Participants received 1000 milligram (mg) abiraterone acetate tablets (as 4\*250 mg tablets) orally once daily along with prednisone 5 mg tablet orally twice daily, from Day 1, Cycle1 (each cycle consist of 28 days) up to radiographic progression of disease and/or unequivocal clinical progression.
- id
- BG000
- title
- Abiraterone Acetate + Prednisone (AAP)
- description
- Participants received placebo matched to abiraterone acetate tablets orally once daily along with prednisone 5 mg tablet orally twice daily, from Day 1, Cycle1 (each cycle consist of 28 days) up to radiographic progression of disease and/or unequivocal clinical progression.
- id
- BG001
- title
- Placebo
- description
- Total of all reporting groups
- id
- BG002
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 8.8
- value
- 70.5
- group Id
- BG001
- spread
- 8.72
- value
- 70.1
- group Id
- BG002
- spread
- 8.76
- value
- 70.3
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- Female
- measurements
- group Id
- BG000
- value
- 546
- group Id
- BG001
- value
- 542
- group Id
- BG002
- value
- 1088
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 60
- group Id
- BG001
- value
- 72
- group Id
- BG002
- value
- 132
- title
- Australia
- categories
- measurements
- group Id
- BG000
- value
- 25
- group Id
- BG001
- value
- 17
- group Id
- BG002
- value
- 42
- title
- Belgium
- categories
- measurements
- group Id
- BG000
- value
- 63
- group Id
- BG001
- value
- 37
- group Id
- BG002
- value
- 100
- title
- Canada
- categories
- measurements
- group Id
- BG000
- value
- 24
- group Id
- BG001
- value
- 29
- group Id
- BG002
- value
- 53
- title
- France
- categories
- measurements
- group Id
- BG000
- value
- 46
- group Id
- BG001
- value
- 32
- group Id
- BG002
- value
- 78
- title
- Germany
- categories
- measurements
- group Id
- BG000
- value
- 7
- group Id
- BG001
- value
- 7
- group Id
- BG002
- value
- 14
- title
- Greece
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 6
- group Id
- BG002
- value
- 7
- title
- Italy
- categories
- measurements
- group Id
- BG000
- value
- 15
- group Id
- BG001
- value
- 15
- group Id
- BG002
- value
- 30
- title
- Netherlands
- categories
- measurements
- group Id
- BG000
- value
- 25
- group Id
- BG001
- value
- 20
- group Id
- BG002
- value
- 45
- title
- Spain
- categories
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 13
- group Id
- BG002
- value
- 17
- title
- Sweden
- categories
- measurements
- group Id
- BG000
- value
- 42
- group Id
- BG001
- value
- 56
- group Id
- BG002
- value
- 98
- title
- United Kingdom
- categories
- measurements
- group Id
- BG000
- value
- 234
- group Id
- BG001
- value
- 238
- group Id
- BG002
- value
- 472
- title
- United States
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Region of Enrollment
- unit Of Measure
- Participants
Complete source fields
- denoms
- counts
- group Id
- BG000
- value
- 546
- group Id
- BG001
- value
- 542
- group Id
- BG002
- value
- 1088
- units
- Participants
- groups
- description
- Participants received 1000 milligram (mg) abiraterone acetate tablets (as 4\*250 mg tablets) orally once daily along with prednisone 5 mg tablet orally twice daily, from Day 1, Cycle1 (each cycle consist of 28 days) up to radiographic progression of disease and/or unequivocal clinical progression.
- id
- BG000
- title
- Abiraterone Acetate + Prednisone (AAP)
- description
- Participants received placebo matched to abiraterone acetate tablets orally once daily along with prednisone 5 mg tablet orally twice daily, from Day 1, Cycle1 (each cycle consist of 28 days) up to radiographic progression of disease and/or unequivocal clinical progression.
- id
- BG001
- title
- Placebo
- description
- Total of all reporting groups
- id
- BG002
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 8.8
- value
- 70.5
- group Id
- BG001
- spread
- 8.72
- value
- 70.1
- group Id
- BG002
- spread
- 8.76
- value
- 70.3
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- Female
- measurements
- group Id
- BG000
- value
- 546
- group Id
- BG001
- value
- 542
- group Id
- BG002
- value
- 1088
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 60
- group Id
- BG001
- value
- 72
- group Id
- BG002
- value
- 132
- title
- Australia
- categories
- measurements
- group Id
- BG000
- value
- 25
- group Id
- BG001
- value
- 17
- group Id
- BG002
- value
- 42
- title
- Belgium
- categories
- measurements
- group Id
- BG000
- value
- 63
- group Id
- BG001
- value
- 37
- group Id
- BG002
- value
- 100
- title
- Canada
- categories
- measurements
- group Id
- BG000
- value
- 24
- group Id
- BG001
- value
- 29
- group Id
- BG002
- value
- 53
- title
- France
- categories
- measurements
- group Id
- BG000
- value
- 46
- group Id
- BG001
- value
- 32
- group Id
- BG002
- value
- 78
- title
- Germany
- categories
- measurements
- group Id
- BG000
- value
- 7
- group Id
- BG001
- value
- 7
- group Id
- BG002
- value
- 14
- title
- Greece
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 6
- group Id
- BG002
- value
- 7
- title
- Italy
- categories
- measurements
- group Id
- BG000
- value
- 15
- group Id
- BG001
- value
- 15
- group Id
- BG002
- value
- 30
- title
- Netherlands
- categories
- measurements
- group Id
- BG000
- value
- 25
- group Id
- BG001
- value
- 20
- group Id
- BG002
- value
- 45
- title
- Spain
- categories
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 13
- group Id
- BG002
- value
- 17
- title
- Sweden
- categories
- measurements
- group Id
- BG000
- value
- 42
- group Id
- BG001
- value
- 56
- group Id
- BG002
- value
- 98
- title
- United Kingdom
- categories
- measurements
- group Id
- BG000
- value
- 234
- group Id
- BG001
- value
- 238
- group Id
- BG002
- value
- 472
- title
- United States
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Region of Enrollment
- unit Of Measure
- Participants
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice
Triangle